Adia Med's Rise, Highlighting 2.5 Years of Growth Toward NASDAQ

Rhea-AI Summary

Adia Med (OTCQB: ADIA) outlines milestones since its January 2024 leadership change, when Larry Powalisz became CEO and bootstrapped a new regenerative medicine strategy. The company acquired and later divested Biolete, secured an 18% stake in Cement Factory, created subsidiaries Adia Med of Winter Park and Adia Labs, and removed its shell status effective June 30, 2024.

By January 2025, Adia Med opened its flagship Winter Park clinic, began treating patients, and in May 2025 retired over 25 million improperly issued shares via court settlement. According to Adia Med, revenue reached $637,145 in the first nine months of 2025, driven by biologics and clinic procedures. The company gained FDA registration for its biologics, filed a provisional patent, and was uplisted to the OTCQB Venture Market in 2025.

Adia Med obtained IRB approvals and ClinicalTrials.gov registration for autism spectrum disorder (ASD), chronic kidney disease, and lower back pain studies, with ASD treatments starting May 1, 2026. With Form 10 effective on February 3, 2026 and a name change advancing through FINRA, the company targets a future NASDAQ uplisting, citing remaining shareholder equity and net revenue requirements.

Positive

• $637,145 revenue in first nine months of 2025 from biologics and clinic procedures
• Retired over 25 million improperly issued shares in May 2025 court settlement
• Removed shell company status effective June 30, 2024
• Uplisted to OTCQB Venture Market in 2025
• Form 10 effective February 3, 2026, achieving full SEC reporting status
• Multiple IRB-approved clinical studies in ASD, CKD, and lower back pain by mid-2026

Negative

• None.

News Market Reaction – ADIA

-12.30%

-12.30% Session close to close

In the Jul 13 session, ADIA declined 12.30%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Winter Park, Florida--(Newsfile Corp. - July 13, 2026) - Adia Med Inc. (OTCQB: ADIA) (formerly Adia Nutrition Inc.), focused on regenerative medicine, stem cell therapies, and biologics, today highlighted its rapid advancement and major milestones achieved since the January 2024 leadership transition.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/304722_adia_med_x_banner.jpg

On January 22, 2024, Larry Powalisz assumed the role of CEO and Director following a change of control, with Rebecca Miller appointed as CFO. Since the transition, Adia Med Inc. has been bootstrap funded by CEO Larry Powalisz as it implemented a new business strategy centered on regenerative healthcare. Adia Med Inc. has been reaching key milestones at a rapid pace, surpassing its expected timelines.

In mid-2024, the company acquired Biolete LLC and formed a strategic partnership with former WWE/TNA star Jeff Sciullo and Cement Factory LLC. It later secured an 18% equity stake in Cement Factory while divesting Biolete to sharpen its regenerative focus. The company also formed key subsidiaries, including Adia Med of Winter Park, LLC, and Adia Labs, LLC. Following these developments, the company successfully removed its shell company status, effective June 30, 2024.

By late 2024, Adia Med leased its flagship clinic at 1561 W. Fairbanks Avenue in Winter Park, Florida. Operations began in January 2025, with the first patients treated and revenue generated from medical procedures. Multiple medical directors were appointed in 2024 and 2025, including Dr. Evan Thomas, MD, PhD, as Medical Director. In May 2025, the company retired over 25 million improperly issued shares through a court settlement, strengthening its capital structure.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/304722_clinic_building_image.jpg

Throughout 2025, revenue grew substantially to $637,145 in the first nine months, driven primarily by biologics sales through Adia Labs and procedures at the Adia Med clinics. The company secured FDA registration for its biologics and filed a provisional patent. In late 2025, following promising results from earlier individual treatments, Adia Med began the process to obtain IRB approval for a clinical study focused on autism spectrum disorder (ASD). In December 2025, the Adia Med of Winter Park ASD research study for children ages 3-12 received IRB approval and was registered on ClinicalTrials.gov, with expansion plans underway. In 2025, the company was successfully uplisted to the OTCQB Venture Market, enhancing transparency and investor access.

In early 2026, recruiting officially began for the ASD study, with treatments scheduled to start on May 1st. The company's Form 10 registration became effective on February 3, 2026, advancing it to full SEC reporting status. It also aligned its SIC code with 2836, which covers biologic products. In February 2026, the company announced plans for four to five new clinical studies in 2026, including expansions in autism research and new rheumatoid arthritis studies with multi-site potential.

On April 15, 2026, the company announced its corporate name change to Adia Med Inc. to better align with its focus on regenerative medicine and biologics. Nevada approved the change, and the FINRA application advanced to the final review stages by early July 2026. All of these efforts form a clear and deliberate strategy to uplist Adia Med to NASDAQ. With only a few key requirements remaining - primarily meeting the necessary shareholder equity and net revenue thresholds - the company is rapidly approaching this major milestone.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/304722_untitled%20design.jpg

In April 2026, the Chronic Kidney Disease (CKD) study (NCT07572890) and Lower Back Pain study (NCT07587047) both received IRB approval and were registered on ClinicalTrials.gov, with recruitment beginning in May. In May 2026, the first group of patients for the ASD study officially began treatment.

In June 2026, CEO Larry Powalisz conducted a podcast interview with stem cell expert Dr. Lyday. The company reported strong Q1 operational momentum while recruiting sales representatives to sell Adia Labs products.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/304722_the_consult_room_podcast_thumbnail.jpg

Additionally, Adia Med created a new division named Adia Life LLC. Adia Life now serves as the primary distribution company for Adia Med Inc. products nationwide. By moving distribution responsibilities to Adia Life, Adia Labs can now focus solely on product development. Adia Life has begun the process of contracting distributors to sell Adia Life products to doctors nationwide.

"Since the January 2024 transition, we have implemented a new business strategy in regenerative medicine and have been reaching milestones at an impressively quick rate while achieving key regulatory milestones, building a growing pipeline of IRB-approved clinical studies, and generating meaningful revenue," said Larry Powalisz, CEO of Adia Med Inc. "We have only just begun, and many updates will follow in the coming weeks as we continue executing on our path to NASDAQ uplisting. We are proud of the progress and remain focused on scaling access to these therapies."

As of July 2026, Adia Med of Winter Park is in its third month of treating the first group of patients for the Autism Spectrum Disorder (ASD) clinical study, which officially began May 1st, 2026. Adia Med operates clinics offering stem cell therapies, PRP, aHSCT, and advanced biologics, supported by products from Adia Labs, including AdiaVita™ and AdiaLink™. The company continues to advance its clinical research and nationwide expansion plans.

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.

About ADIA Med Inc.:

Adia Med Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Med Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Med Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_MED

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304722

FAQ

What key milestones has Adia Med (OTCQB: ADIA) achieved on its path toward a potential NASDAQ uplisting?

Adia Med reports regulatory, clinical, and capital-structure steps supporting a potential future NASDAQ uplisting. According to Adia Med, it removed shell status, uplisted to OTCQB, made Form 10 effective, advanced a corporate name change, and notes remaining shareholder equity and net revenue requirements for a NASDAQ move.

How much revenue did Adia Med (ADIA) generate in the first nine months of 2025?

Adia Med reports revenue of $637,145 for the first nine months of 2025. According to Adia Med, this revenue was driven primarily by biologics sales through Adia Labs and medical procedures performed at Adia Med clinics, reflecting growing commercial activity in regenerative medicine.

What clinical trials is Adia Med (ADIA) conducting in 2025–2026, including the ASD study?

Adia Med is sponsoring IRB-approved studies in autism spectrum disorder, chronic kidney disease, and lower back pain. According to Adia Med, the ASD study for children 3–12 began treatments on May 1, 2026, with CKD (NCT07572890) and lower back pain (NCT07587047) trials starting recruitment in May 2026.

What was the impact of Adia Med’s 25 million share retirement in May 2025 for ADIA investors?

Adia Med retired over 25 million improperly issued shares through a May 2025 court settlement. According to Adia Med, this action strengthened its capital structure by reducing outstanding shares, which can improve per-share ownership metrics and support its broader uplisting and financing strategy.

What does Adia Med’s Form 10 effectiveness on February 3, 2026 mean for ADIA shareholders?

The Form 10 effectiveness made Adia Med a full SEC reporting company as of February 3, 2026. According to Adia Med, this increases disclosure, transparency, and regulatory oversight, factors that can enhance investor confidence and are typically required for higher-tier exchange listings.

How is Adia Life LLC positioned within Adia Med’s (ADIA) business model?

Adia Life LLC functions as Adia Med’s primary product distribution division across the United States. According to Adia Med, shifting distribution to Adia Life allows Adia Labs to focus on product development while Adia Life contracts distributors to sell products like AdiaVita and AdiaLink to doctors nationwide.

What services and therapies are offered at Adia Med of Winter Park as of July 2026?

Adia Med of Winter Park offers stem cell therapies, PRP, aHSCT, and advanced biologics-based procedures. According to Adia Med, the clinic also hosts the ASD clinical study, which has been treating its first patient group since May 1, 2026, alongside broader regenerative medicine services.